8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 28, 2003

LIPID SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	0-497	43-0433090
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S Employer Identification No.)

7068 Koll Center Parkway, Suite 401, Pleasanton, California	94566
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (925) 249-4000

TABLE OF CONTENTS

	Item 7. Financial Statements and Exhibits
	Item 9. Regulation FD Disclosure
SIGNATURE
EXHIBIT INDEX
EX-99.1
EX-99.2

Item 7. Financial Statements and Exhibits

(c) Exhibits

Exhibit	Description
99.1	Lipid Sciences, Inc. Press Release dated January 28, 2003
99.2	Letter to Stockholders from the Chairman of the Board of Lipid Sciences, Inc.

Item 9. Regulation FD Disclosure

     On January 28, 2003 Lipid Sciences, Inc., a Delaware corporation, issued a press release entitled “Lipid Sciences Announces New Strategic Direction-Will Focus on Viral Application, Restructure Business Operations”. As described in such press release, effective immediately, the Company will be focusing its research and development investment on its proprietary Viral Pathogen Inactivation platform. This new direction is part of a comprehensive strategic plan being implemented by the Company, as further described in such press release. As part of the cost-savings goal of the strategic plan, Barry D. Michaels has stepped down as Chief Financial Officer and certain other management positions are being eliminated.

     In addition, on January 28, 2003 Lipid Sciences, Inc. forwarded to its stockholders a letter from the Chairman of the Board that enclosed the press release mentioned above. A copy of the press release and the letter from the Chairman of the Board are attached to this Form 8-K as Exhibit 99.1 and 99.2 and are incorporated herein by reference.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Lipid Sciences, Inc.
Date: January 28, 2003	By:	/s/ Sandra Gardiner
	Name: Sandra Gardiner Title: Chief Accounting Officer

EXHIBIT INDEX

Exhibit	Description
99.1	Lipid Sciences, Inc. Press Release dated January 28, 2003
99.2	Letter to Stockholders from the Chairman of the Board of Lipid Sciences, Inc.

EX-99.1 3 p67422exv99w1.htm EX-99.1

Exhibit 99.1

FOR FURTHER INFORMATION CONTACT:

AT THE COMPANY:
Deborah S. Lorenz
Vice President, Investor Relations &
Corporate Communications
925-249-4031
dlorenz@lipidsciences.com

FOR IMMEDIATE RELEASE
TUESDAY, JANUARY 28, 2003

LIPID SCIENCES ANNOUNCES NEW STRATEGIC DIRECTION

Will Focus on Viral Application, Restructure Business Operations

PLEASANTON, Calif., January 28, 2003—Lipid Sciences, Inc. (Nasdaq: LIPD), today announced a new strategic direction for the Company and the application and development of its novel technology of plasma delipidation. LIPD is a development-stage biotechnology company engaged in the research and development of products and processes to treat major medical indications, such as cardiovascular disease, HIV and other viral infections, in which lipids, or fat components, play a key role. Effective immediately, the Company will be focusing its research and development investment on its proprietary Viral Pathogen Inactivation (VPI™) platform. The first indication being pursued by LIPD to demonstrate the efficacy of the application of the VPI platform technology is HIV. HIV is a lipid-enveloped virus that infects an estimated five million people and kills an estimated three million people each year. The VPI technology successfully inactivates the HIV particle and has the potential to be a therapeutic treatment for this disease.

Current studies in support of this application of the VPI platform to HIV have been conducted in vitro and in mice under the supervision of Dr. Aftab Ansari at Emory University and Dr. James E. K. Hildreth at Johns Hopkins University and have demonstrated both safety and immunogenicity. Non-human primate studies are planned to demonstrate safety and efficacy in a human surrogate model. Once successfully completed, the non-human primate study would provide the basis for future submission to the FDA for the initiation of a Phase 1 Human Clinical Trial.

The preliminary results from the Company’s Phase 1 Human Safety Trial in Australia have advanced the science and improved the safety of the Company’s proprietary delipidation process, which forms the basis of the VPI platform and the Company’s proprietary Vascular Lipid Removal (VLR™) platform. The Company believes it has identified and mitigated the cause of the previously announced adverse events

experienced in that trial. For strategic reasons, however, the Company has determined to align its clinical trial efforts toward a VPI platform and U.S.-based clinical trials. Therefore, the Company is discontinuing the clinical trial in Australia.

This new direction is part of a comprehensive strategic plan being implemented by the Company. In conjunction with the adoption of that plan, Lipid Sciences also announced today that it will undertake a restructuring of its business operations. This restructuring is projected to reduce operating expenses in the second half of 2003 by approximately 30% to 40% when measured against the same period in 2002. Savings will come primarily from staff reductions, the termination of the Company’s Phase 1 trial and cessation of operations in Australia, and the focusing of the Company’s research and development investment on the viral application of LIPD’s technology. Richard G. Babbitt, Chairman of Lipid Sciences, commented, “This restructuring action will allow us to move aggressively with the development of our viral platform, with the first clinical indication being HIV, while we also continue to advance our cardiovascular platform. Our strategic plan calls for the targeting of our R & D efforts to maximize shareholder value in the months to come. We will now join together to begin the exhilarating process of focusing our efforts to assure our future.”

The strategic plan was recommended by the management team and approved by the Board of Directors. As part of the cost-savings goal of the strategic plan, Barry D. Michaels has stepped down as Chief Financial Officer and certain other management positions are being eliminated. Sandra Gardiner, the Company’s Vice President, Controller and Corporate Secretary, will assume the newly created position of Chief Accounting Officer. Prior to joining Lipid Sciences two years ago, Ms. Gardiner spent eight years as Controller and Director of Administration of Cardima, Inc., a publicly traded medical equipment manufacturer. In related appointments, Marc Bellotti, currently Vice President of Product Development, will assume the position of Vice President, Research and Development; Dale Richardson, currently Vice President of Marketing and Sales, will become Vice President, Business Development.

“Let me take this opportunity to thank all of our continuing and departing employees for the contributions they have made on behalf of Lipid Sciences. While change will be the norm as we move toward commercialization, I would like to assure you that the Company is in a financially stable position to implement this new strategic direction,” noted Mr. Babbitt.

Lipid Sciences, Inc. is a development-stage biotechnology company that is researching and developing products and processes to treat major medical conditions, such as cardiovascular disease, HIV and other viral infections, in which lipids, or fat components, play a key role. The Company’s technologies are based on a patented process that selectively removes lipids from proteins in blood plasma without disrupting protein function. This process of lipid removal, known as plasma delipidation, potentially reverses the condition while enhancing the body’s natural ability to heal itself. The Company believes that this unique delipidation process has the potential for far-reaching implications for human health. It may reverse cardio- and cerebrovascular disease, as well as provide an effective therapeutic effect on many infectious agents, including the viruses that cause AIDS, Hepatitis B, Hepatitis C, and Herpes.

Forward-Looking Statements

This release contains forward-looking statements concerning plans, objectives, goals, strategies, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds; our inability to receive regulatory approval for our technology, which is only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International; our reliance on collaborations with strategic partners; competition in our industry; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; product liability claims; economic downturn in the real estate market; our dependence on key personnel; shares of common stock will become available for sale after expiration of lock-up periods; and existing stockholders may experience dilution if additional shares are issued to former NZ Corporation stockholders who have perfected certain rights.

The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC’s Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov. Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.

EX-99.2 4 p67422exv99w2.htm EX-99.2

Exhibit 99.2

January 28, 2003

Dear Stockholder:

The idea of change and evolution is not new in today’s marketplace. In fact, change will be the norm at Lipid Sciences as we move toward commercialization of our novel technology and continue on the path of value creation for our stockholders as well as our business partners. To that end, we have announced that the Company is taking a new strategic direction.

We will focus our R & D investment on our proprietary Viral Pathogen Inactivation platform, with the first indication being HIV—a lipid-enveloped virus that infects an estimated five million people and kills about three million people each year. Current studies being conducted by Drs. Ansari and Hildreth, members of our Viral Advisory Board, have demonstrated both safety and immunogenicity of this process. The successful conclusion of these studies will be an important first step toward a goal of FDA approval for a Phase 1 Human clinical trial based in the U.S.

As a result of the adoption of this new strategic focus, we have made the decision to discontinue the human clinical trial in Australia. The preliminary results for that Phase 1 safety trial have advanced the science and improved the safety of our proprietary delipidation process—critical to both our viral and cardiovascular technology platforms.

The Board of Directors and the management team have also taken a long, hard look at the goals of Lipid Sciences and operations in the current economic environment. We will therefore undertake a restructuring of our business operations. This restructuring is projected to reduce operating expenses in the second-half of 2003 by 30%-40%, when measured against the same period in 2002. Savings will come from staff reductions, cessation of operations in Australia, our ability to more aggressively focus R & D efforts on the viral platform while continuing to advance the cardiovascular platform. I have enclosed a press release dated January 28, 2003 providing additional details. Our search for a Chief Executive Officer continues with many strong candidates having been identified.

I want to assure you that these decisions were not made hastily and that they form the basis of a sound strategic plan. These decisions are correct for Lipid Sciences, and the business is on the right track. Let me assure you that we are in a financially stable position to implement this new strategic direction.

Change is sometimes unsettling, but with change comes the opportunity for bold and decisive action. It is our belief that greater opportunities will be achieved through these changes with a minimal amount of disruption to the organization and our goals.

I will continue to update you on our progress and appreciate your continuing support.

Sincerely,

Richard G. Babbitt
Chairman of the Board
Enclosure

Forward-Looking Statements
This letter to stockholders contains forward-looking statements concerning plans, objectives, goals, strategies, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this letter reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds; our inability to receive regulatory approval for our technology, which is only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International; our reliance on collaborations with strategic partners; competition in our industry; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; product liability claims; economic downturn in the real estate market; our dependence on key personnel; shares of common stock will become available for sale after expiration of lock-up periods; and existing stockholders may experience dilution if additional shares are issued to former NZ Corporation stockholders who have perfected certain rights.

7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566-3111
Tel: 925-249-4000 Fax: 925-249-4040

GRAPHIC 5 p67422p67422z0002.jpg GRAPHIC begin 644 p67422p67422z0002.jpg M_]C_X``02D9)1@`!`@$`7@!>``#_X0B=17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!>```` M`0```%X````!061O8F4@4&AO=&]S:&]P(#7U5F9VAI:FML;6YO8W1U=G=X>7 MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_ MV@`,`P$``A$#$0`_`/4A;40PA[2+#%9D>XP70S][VM,7,L?8_&ZCB56NMM]/T+MV=C?X7TOT5EGL1 M*_J=UQCFY7K8YM:X/^Q>I?Z!8+6V_8OM3_4S/LS]OVK\^O[;_P!IK,3]$DIL M_6OZZY'1KO1Z?AMS#4UC[['O+6CU"[TZ:MC7NLM?M^E_Y\6[T7JK>JX%62:G MXM[F@WXENEE3C^98WY?HW?GL7EN:_$P[>GXV$UUW4.AMVV.J%AJRC78ZT48M M1]1[Z<-S[ZOMEC-^_P#TW\XNCZ#];\%G6,@]4KMPG.Q'WU/=#@:Z@^MOO^A=_A/8AE]P2QQACN)'%EE>L/\%L#%#VC(DQD!Z1^\7ODEDXW MUFZ7;7CNR7.Z?;EVFG&HR]M;['`-?^@][ZKZW>I7MMIMLJ]2ST/Y_P#1)J_K M9]7GTMMLSJ:-U%>2YESVL_&95FU/?F[OL[`[W M.V';8-OTF['_`*/W_P"%_1?SB2G022224Y.-TW&R\C+OSFC+/KN;2R[WLK8& ML&RFFS=6S>_?999M]1^__1LJ8S/=;Z64.D9%F19@U6W.BMMUUKV,;B6TXM]N M.VV[[.RSJ#_^.JQZ:+O5J^T^KT&/0:?5EV[U+'6<1&Z/:J-O2BT78EF M0'UOC'R,>EI;79D8V2^:Z,=MM6730SU/\)59Z"L=1S+NH86&.GM=Z^14@&75U6;?I>IEVXM%U7^B]97:L?J%V57D9KJZZZ)-5%)>[WD&OU;;G>CZG MZ-]C64?9_P#A/?\`H_36!TMN'DY-^_>+G?H6Q'IUDNO?5_*W95^19_Q7H4_X M!.B0/IJ$-3J61=U&K'JZ980^['MS*GAVV?T?IX;7Z.V[[\JN]N]O_:95]G1X MIKKJLZ/U`/8*KKJW,:QN06. MR3MQK*V[745@OMHK9)>RS[/DWWV5^W9Z?IT>GZ=::_%ZUF4'#R7XS*7^V^^M MKRY[/SVU8]NYF,^QOY[LC+]'_A$\$;`Z#^7^$I__T/54DDDE/,'ZJ.Z;DYF7 MTPF_[81^KV%H-39=8YF-:Z/T3K;-_I/4\/ZJ]*PVW=6Z@T5]0?18RW+;8YOH MUN!:\T/!:VBUM7T\JO\`2_\`"+I%7S_Z#D?S7\T_^D?S/T3_`$C_`(#_`$O_ M``:K1]O[[.^/WN#U7\G!Z-O_`!MMS][[J+X>#BU_SO7AX_ZK@=,^JWU,FS(LK^U!D/]E^;D,Q=CZ_]'^F]*M-A?5;ZO8F5 MA64Y=OVK&LLM#O7#;,BRWT[7ORG5>G9DM_H_Z)GZ#T_19=796JV-_1\C_D/^ M:_P?T?IT?S__``?_`+L_9U:;_3,+_DC_``/_`!GT:?\`D_\`]U_^"^S)>GQ5 MKX/2))))J5))))*4DDDDI22222G_V?_M#2Y0:&]T;W-H;W`@,RXP`#A"24T$ M)0``````$``````````````````````X0DE-`^T``````!``7@````$``0!> M`````0`!.$))300F```````.`````````````#^````X0DE-!`T```````0` M``!X.$))3009```````$````'CA"24T#\P``````"0```````````0`X0DE- M!`H```````$``#A"24TG$```````"@`!``````````$X0DE-`_4``````$@` M+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8```````$`,@````$`6@`` M``8```````$`-0````$`+0````8```````$X0DE-`_@``````'```/______ M______________________\#Z`````#_____________________________ M`^@`````_____________________________P/H`````/______________ M______________\#Z```.$))300(```````0`````0```D````)``````#A" M24T$'@``````!``````X0DE-!!H``````TL````&``````````````!N```" M'`````L`4``V`#<`-``R`#(`6@`P`#``,``R`````0`````````````````` M```````!``````````````(<````;@`````````````````````!```````` M`````````````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J M8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO M;F<``````````$)T;VUL;VYG````;@````!29VAT;&]N9P```AP````&7!E`````$YO;F4````)=&]P3W5T/S1B>4I(6TE<34Y/2EM<75Y?56 M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$# M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:F MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]2%M1#"'M(L,5F1[C!=# M/WO:UR?>S?Z>X;XW;9UCC=M7$.^JWUKKZ.W!%^-LZ;3>.GUXQQ$K^IW7&.;E>MCFUK@_[%ZE_H%@M;;]B^U/]3,^ MS/V_:OSZ_MO_`&FLQ/T22FS]:_KKD=&N]'I^&W,-36/OL>\M:/4+O3IJV->Z MRU^WZ7_GQ;O1>JMZK@59)J?BWN:#?B6Z65./YEC?E^C=^>Q>6YK\3#MZ?C83 M77=0Z&W;8ZH6&K*-=CK11BU'U'OIPW/OJ^V6,W[_`/3?SBZ/H/UOP6=8R#U2 MNW"<[$??4]T.!KJ!R^263C?6;I=M>.[)<[I]N7::<:C+VUOL<`U_Z#WOJOK= MZE>VVFVRKU+/0_G_`-$FK^MGU>?2VVS.IHW45Y+F7/:QS*[16^OU9.UC]M]/ ML_X:K_2UHM=UTEE_\Z/J[^@GJ6,/M59NH)L:`ZMN[=9)/M;^CL^G_HK?]%8B M4_6#HE[\9E6;4]^;N^SL#O<[8=M@V_2;L?\`H_?_`(7]%_.)*=!))))3DXW3 M<;+R,N_.:,L^NYM++O>RM@:P;*:;-U;-[]]EEFWU'[_]&RIC,]UOI90Z1D69 M%F#5;]I-9K?711=BW-:]KMMCL2NYMU>Q]5OI? MSE7K4WI3GY-5#WLIZ+1=B69`?6^,?(QZ6EM=F1C9+YKHQVVU9=-#/4_PE5GH M*QU',NZAA88Z>UWKY%1SJANV1Z`9=759M^EZF7;BT75?Z+UE=JQ^H795>1FN MKKKHDU44E[O>0:_5MN=Z/J?HWV-91]G_`.$]_P"C]-8'2VX>3DW[]XN=^A;$ M>G62Z]]7\K=E7Y%G_%>A3_@$Z)`^FH0U.I9%W4:L>KIEA#[L>W,J>';9_1^G MAM?H[;OORJ[V[V_]IE7V='BFNNJSH_4`]@JNNKX/5?R<'HV_\`&VW/WONHOAX. M+7_.]>'C_JN!TSZK?5S"%-V#EV,L;8^RV]EK6&^2QMM.2VEM5+J-^+3[**J? MYG_ALGUFI^IWU7JR*#13<__``E?_"6* MGD_S=O\`R%])G\W_`#O%G\S_`-VO^X?_``N]/3_-9?\`R1_1&_T;^9^G_A/_ M`$3_`-;5OT^+3]7@W[?JS]7+;_*=5Z=F2W^C_H MF?H/3]%EU=E:K8W]'R/^0_YK_!_1^G1_/_\`!_\`NS]G5IO],PO^2/\``_\` M&?1I_P"3_P#W7_X+[,EZ?%6O@](DDDFI4DDDDI22222E))))*?_9`#A"24T$ M(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`G)E4WI.5&-Z:V,Y9"<_/@H\/V%D;V)E+7AA<"UF:6QT97)S(&5S8STB M0U(B/SX*/'@Z>&%P;65T82!X;6QN#IX M87!T:STG6$U0('1O;VQK:70@,BXX+C(M,S,L(&9R86UE=V]R:R`Q+C4G/@H\ M"UN&%P34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W`Z,6%E.39A M,#4M,S,R,"TQ,60W+3EA8S4M.3ED9F%E-S`P.3)A/"]X87!-33I$;V-U;65N M=$E$/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX87!M M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*/#]X<&%C:V5T(&5N9#TG=R<_/O_B#%A)0T-?4%)/1DE,10`!`0`` M#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C%```8VEA96B`````````D MH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W M`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(! M.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J(" MK`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B M`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$ MTP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G M!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&09!ZP' MOP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY M"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+ M@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI M#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0 M)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$)%ZX7TA?W&!L80!AE&(H8KQC5 M&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;8QN*&[(;VAP"'"H< M4AQ['*,0!YJ'I0>OA[I'Q,?/A]I'Y0?OQ_J M(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B--@U$S5--8Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$25^!8+UA]6,M9&EEI6;A:!UI66J9: M]5M%6Y5;Y5PU7(9O5\/7V%?LV`%8%=@JF#\84]AHF'U M8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-I MFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z M<95Q\')+%V/G:;=OAW5G>S>!%X;GC,>2IY MB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'- M@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2* MRHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.V ME""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>= M9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;] MIVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:QK_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;& MP\=!Q[_(/%$XIZ#+HO.E& MZ=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#U MWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N``Y!9&]B M90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0(" M`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`__``!$(`&X"'`,!$0`"$0$#$0'_W0`$`$3_Q`&B````!@(#`0`` M```````````'"`8%!`D#"@(!``L!```&`P$!`0````````````8%!`,'`@@! M"0`*"Q```@$#!`$#`P(#`P,"!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)44(6 M820S%U)Q@1ABD25#H;'P)C1R"AG!T34GX5,V@O&2HD147J%AH>(B8J4 ME9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT]?;W M^/GZ$0`"`0,"!`0#!00$!`8&!6T!`@,1!"$2!3$&`"(305$',F$4<0A"@2.1 M%5*A8A8S";$DP=%#$A:.SP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F]F=W MAY>GM\?7Y_=(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK: MZOK_V@`,`P$``A$#$0`_`-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]T!'RE[`W%U/\9/D9VGM"6DAW;UIT1V[V!M>:OI5K MJ&+<6S>O]P[CPDM;1.RI64D>2QL1DB)`D0%2>?=D`+*#P)ZI(2J.PX@'JIOI M[^<-L;IS^3K\4OYA/SEW%)D>P>[>N]M"AV1U9M6FEWQW5W'N2IS$6&Z]ZDZ_ MIJNFIZO<.;3&EEC:>GH:2)'FJ)X8E+>]E22:#%!UH-1>XYJ?Y$]`;MSKK^?] M_,8QK=@=C=^==?R8^C=R1T64V1T3U7U]C?D9\N&PDAD'VO;_`&'NZIVGMK8N M7KJ%XNM:V7!4L5*K%=< M#Y"59`"+B_&@X\UQ^7_0/7O#;B'S_MO^@N@\W/\`.3^:%_*'S>&K_P":/B]@ M_-KX"Y'/87:^1_F!?&O8E3L#M[HDY>>EPV*W/\E_CM0&LPU3MBOSE7%%+4;7 MDG%'3ZI!4U^1GI,1-L*LE=.&_E_J^=?R`J>O%GC^*I7^?\@/R%/S)('6Q]L_ M=^UNP-J;;WUL?<&)W9LW>.#Q>YMJ[GP-=!D\)N#;^;HHG000"#CI1^]=;ZJ+_F`_P`V#;7Q0[$VC\3OCITU MNWYK_P`PCM3%G+]=?%+K#*XW#G;VW/U2]C=Z]A9,38+J+KNF@5FCJ*Q)*BLD M\8$<-(\M?3W5:\30?ZO]7^"IQU1FIPR?]7\_]1H,]%&@^`O\\'Y514F\OEI_ M-EP_PZ^_EJ)V^.O\O7INB7!;8H9YA-14TW?W8V9I=_Y?-P4A\57$]'6T<4X; MP5,\=G;>I!@+_J_,'_`.JE':E7Q^?\J$4_,G_.YU'\H+^8]U[6T^?^/7\^_Y MET.9Q[154.)^376G7'R8VGEIH3Y),?E,;E\CM):>@KV'C:2..66!&+*'8`>_ M:P>*C^7^0`_SZ]X;#@_^'_*2/Y'I/;4_FP?,#^7_`-F[%Z)_G?=,]=[(V)V' MFZ;:?6'\R7XT5.=RGQ3W#N.N,HQ6`[MVSN"D@W1TAFZI8U2;(U"QXYJAVF%) M38NGJ,C%X)KKH_U?ZOV>5:T'7C)HH'_U8]?^*/G2@)ZV+*@OD<7.<5D8Z>2O MH)#C1@CD*JZ,Z:D!%16E1YBHR M*\*].,"5(5J&G'T^?547\FOYD=R_+KXS]D8KY/S8>?Y8_%/Y.][_`!.^2-3M MW#4&W-N97?W5V[9*K%YS;&#H6`IL!4[)W%C*43-%"*G(456ZH%L/Z/+&U M\M[_`&[NJ]_1X;'T]'246+W3!/EJ3'RQPQ" MLH\0E0ZK-)*BG/NKRML&Q7NQ;MRBLG]5MSLQ)$6)(\1#21`69VJJ-"SJS$H\ MC)\(4E-LM[)<)<6]S.SW<1SJ4*P4EE&H*%4]Z2`%5`*@$5^(W4>XIZ.^O>_= M>Z)E_,1^56-^$?P>^4'RHKJF@IZWIWJ+<^=VA'E()JG'93LS)P)MGJ?;U=#` MK2&EW-V;G,3CG/"HM5J8A02!7R/R\W-?-VP;!H=H;BX7Q=%`P@2LD[+6@U+" MDC`>9%.D6XW#6ME<3(P$M**2"P#L0J5`SIU$:O05)H.LGPFWSW75?!OH#M3Y ME[FVU3]SYCI#`=H]WY^/%XS8^V]LU>?PK[UR-)D:&%H,1@XMD8&NCHZ^4%(/ M+12S$A23[WS=8[6O..];7RM:L=N2[,$"*6D+E"(ZH35V$D@+1@U;2RCCTSML MTO[KM[J^FJQC+EF"H0IJRZP**"J$!Z4%03CJG7;WSU_F3_S:]Q;G7^5#B>N? MB?\`!_:^[\QLIOYA?R4V9DMY;\[KGPE<JFCEB5A MP&7BS3>[/*-N$CVGV@V>.`<1.(KIJ>='>U1J^A-3ZUZ8;ER]FDD>??)B"3I" M/?S"NC,/2YWLKH#/ M9:ESNV]Z[0GE@IX^T>E-W4\\U/NW9DTE93/41I)4_9"MA\-7D(=54`QSS[?1 M]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2'[%[.ZWZAVKD-]=K[_V9UGLK M$A3D]V[^W/A=H[;H-=_&M5FL_6T&.ADE(LBM(&<\*"?;]M:W-Y*L%I;O+.>" MHI8G\@">G[>VN+N58+6!Y)CP506)_(5/52>YO^%"W\H3:F>J-OY'Y>86KGI: MEJ2?)8/KKMO/X'RI,\,CT^;Q.Q*O'UU,K(2)J=Y870AD9E(/L61^WW-TD8E& MT$`BM"\8/["P(_/H51\@\V21B3]U$+3\3QJ?V%A3[#GJQ;XY?+_XN_+O;4F[ M?C-WSUAW5AJ6.&3*#8FZ\9ELQM\U"JT%/NK;(FCW+M.MD5P13Y*DI)[,#HY' ML.7^U;EM_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=> MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HJ7SP_[(=^9? M_BJ7R(_]]#O#W>/^T3[1TW+_`&4G^E/^#K5&_P"$U'2LOSPPG0/S'[MQ/\9Z M8_EI]-[4^'GPCV%FRU7@:3ONKPN&[,^3OR/FVYD<<((=W8^LW5A-L8#)4\\L M+P8V24HE90TTL-F:B@#S`_EC_./\&#U5%JS:AP)_F:_YC^8\QUNS>VNGNO>_ M=>Z2^]]E;1[*V9NWKOL#;>&WCL3?FVLYLW>FT=Q4%/EKIX(M,$42+9P*!A3_`%?\70?9U1"OPE[S^4]9AEW7N78^W:;#]5[%\%76/V!W-OC)T>SNJ-FF@QM139>LQV6W MOFJ,Y+[-C5PXF*JGB5FBM[JHJ>K,:`FO^K^7#CT7'^4#_+MK_AITSE^X?D#6 MOV3_`#!_EC40]L_,OO#/SIE]S9/>FX&.6H^J\%DY*>$XCKWJ^EJ8\=2X^D$= M$U5!+-&B0FF@I[.020O#_5_+T^7Y]:1:`$\?]7\_7U/Y=6_>Z=7Z][]U[H(> M^^A>HOE!TYV%T#WSL7"]D]2=I[;KMJ[VV=GHI6I,GC*U5:.>DJZ66GR.%SF) MK(XJS&Y*BFI\AC,A!#5TDT-3#%*FP2I!''K1`8$'AU2I_)-["[0^/N]_E;_) MT^0N\,EO7?/\O_,[7R_QCW_N>KQW]Y.VO@KV5#.W3F0E@I=#Y#)=4-1QX3+S M1HM+CS7T&/0?Y/=KN*@/6M?]7^5ZBG$I*)#HFC<8_P"L_LILVZ"AO^7[^2W?-6-M<%&65_-55WMX M(A\/8Y%#JJ0I*MES`UMV".Y2H[2"6HSJ*TTM\%R[4(*U6J]U>MA3W"?0CZ][ M]U[K74_F6Q_[.3_-K_E5?R\Z2DCW!U[T;G]T_P`S;Y-4$7VLXPV*Z;@KMF?' M.3*QRU2+)B,[VADJW$9&B,4LD]/FJ=](A\A:;N11_5CVXY^YU=M%Y=J-MM3J M8%C)I:X``'%5:.9&)"AK=QW-0`/[@SW>YV>WH'\):,]%!6A)(#%L<(S&P`+` M3(:"H;IQWLDWPT_X41]6[SIX*7#]3?S4'\HZ0EQ6W\3"`/XA75DXB5IS)JU9B/FCV2W.W/=NG+E^DB43(M+I MB"@(%7+3-/-(3\$<"U.FE*2LUGS#`VH^#$#R1E5CH<[@J:7%50:R24==+']6'NOL'MEINGN9M"WJ!TB21U!SWE? M#5A_20R>(GHZ*>`ZUS/=/:;6\D<;-0UHI()\-6E"@C^(QA2*9!(IGJ[/I[J7 M8/0O5'6_275>`AVOUMU-LC;/7FQ=O02SU*XG:VT;SN5_NVX2Z[ZYF:20@!06_OY:?\TK;<%1@^S/BU\U.JNI>R-Q8"*@HLON_XJ]VS9W'=H[&S=:*4 M5V:A@-,]/AZ>HG^UQ_\`>'*2(@DJG8SS[+RW._6?//M[*X>QW#;))(DR>QW=T(DCDRRA-6F-))]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]T'?;G:.TND^K]_]N[\KUQNS^N-IYS>&X:HE/(,=@Z":NEIZ5'91 M/7US1""FB!U33R(BW9@/:FSM)KZ[M[.W6LTKA1]I-,_(<3Z#I1:6TMY?RZ^<9\^_E5\@_YD':F8WSV/F\UC>L:#(U`ZPZ=H%.-34]9";%MNW\NVR06Z`W)`UR&FICQ.>.D>2\`/4U/50?9_ M2@QD,Y--H*@V/C4$$'_@O%[^Q;!=:J^G0MMKS705Z`CHWY%]^?"CNC;_`';\ M=NQ=Q=:]B;5JXI(\AA,A64M!N#%+5P559MC=N*IYH:3B[?\`;;>[M766%7@;BI%1 M6A%?D14Z2*$>1Z^L'_*A_F*;-_F<_#C8?R0P5!C]L[V\]=LON7K^@JGJHMA] MH;=9(\UC*9IIJBJ_@>;HIJ;+XHS2//\`PRO@$I\RR`8R;_L[[+?O;59K=AJC M8BFI:D?M4@J:8J"1BG6.&^[2^SWQ@&HVSC5&QXLM2,\,JP*F@H2I(P1U9/[) M.B;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][] MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HJ7SP_[(=^9?_BJ7R(_]]#O# MW>/^T3[1TW+_`&4G^E/^#JO#_A.'UYB.MOY*_P`$\7B::"%MQ]>[L[#RM1'& MBS5^7[$[1WUO&JJ:R4#743P19B.F1G)*04\<8LJ*!IJ5%.%!_@ZVE2"3QJ?\ M)_R=7>>Z]7Z][]U[KWOW7NM??X-T\-'_`,*`/YZ(I4\(R_5?\L_)Y(*S::NO MI>A]PXNGJ9%8D"2*@@6(:;"P^ER2;M\*8\O\IZ;7XWSY_P"1>F_^;=!C._?Y MDW\C#X1YJ>M.U=P?*+MKYH[SH($5J*KE^%_4>3WYUW199&$B5.,S6Y\E444\ M+J4DBE(/)NNUPCGS_P`G_%TZT^713_J/^R-76PQ[;Z=Z][]U[KWOW7NO>_=> MZU\/EO+C>C/^%#G\I[M#$4D5/EOFA\6/F[\1=_U\C,3M/Y&[)%3` M+PSNN\LJL"L`LC"1=3%8D47!&@@CA_L?YCU0@ZP0<>?\_P#*1_J'67^?K3U? M0VW?@G_,_P`--F*:J_ER?,#8FY.RYL#`M1EZOXP_(;+[>Z=^0.WL;$[HCUVZ M:&IP^/4-Z#%/("1P?LWNO6^M;W^2VB?+;YJ_P`UO^:AD10Y_;G:'?,/P]^+.[(C M.8G^/'QNCBQN3S6URWA0[9[4RD6`R,Q>,O\`Q'%2V(;R:IX]UR>6N5/;OV\C M+1SV]I]7=QFF+B8M19`*_J0R-=*IKF*1,<*!38`E[?;GN]$8,VE'&NNEPK8+ M4&EH%M20HH'5\DUZ&/\`X4-]3[PRGP6Q'RWZBQL59WQ_+B[QZI^;?6$KP^97 MH^J-S44O8E!DD+JD^VH=DUE3E\C3M=:B/#*A!O8D_LINUM;6L\D4@!!`>-BC`$8(#` MT(P>/1U!,MQ!#<(&".@8`@@@$5H0<@^H.0<'H0/:'IWK7N^$U0?EU_.^_F5_ M+W^)5>2ZY^%G7^P?Y:G2P>D#8B?>,62B[2^3\\9F(-!N/9/9V(3$^6(,U509 M'UNJ!$,W\W+_`%9]I.0N6#$%O]TFDW.?/<$*A+8BGQ1S0/&Q!^"2`T%220Y8 M@W6^[C=G5HC0(*H`#W%::CW$QLDK"@"E)P_OB1G\C6R/QX^3L.V(Z?`Q=O[)[.VQBI\-2R;K--]UE9FIH-NT];*WAK8F M=J"DD[F3VBEWP77-GMG=6VXU*;?71W; M/6W<>RJPVIMV]6[XVSO[;S[ML MMQ]+O&V7%K!!J.CR"ZMKH,UM<)(JD@Z6#4(-"#0X M((((.000>A/]EW3_`$B=_P#6O7/:^W_[I=I;`V3V5M7^)8O,_P!V=_[5P6\M MO_Q?"5D>0PV5_@VXJ#(X[^)8BOA2>EG\?EIYE#QLK`'VML-RW':KCZO:[^>V MNM++KB=HWTL*,NI"#I8885H1@XZ8N+6VNX_!N[>.6&H.EU#"H-0:$$5!R#Y' MI;>T73_7_]+OZG=E%O'I[%3Y1]T8&L MV+41TF\*2K,N,BQ;5.WJJ01U,<=0[QL&%O2UO=>IT='W[KW1./F'_,#^''P" MPO7VX?F!WOM?I#$]J;L_N3L&HW!CMSYB;<&>C6E>N*4.TL#N&OQ^#PL=?`^2 MRU7%!BL8D\35=3"LB%O=;IT<&FJ:>LIX*NDFBJ:6JABJ::HA=9(9Z>=%EAFB MD0E9(I8V#*P-B#?W[K76;W[KW7O?NO=$S^(_\PKX9?.^K[@H?B3WUM;NJLZ$ MW=2[([7I]OX[=&*EVMG<@V63$S(NZ<#@3N#;>=?`5ZX[-XO[W"Y%J&H6FJI3 M!*$]UZE.CF>_=>Z)_P#+#Y^_#;X+Q[!E^7'R#V%T0G:-1N*FZ_.]JG(PMNF7 M:*X)MSG&ICL=D',.#&Y\?]S)($CC^\BNWJ'OW7J5Z(=_/[WQD=I?R_NEABD2D+QW0$LX%PO^ M%_OWF/OOWW*&\[A[>^SUA;7>]6;%+O<)P M9(()E)#P00]HFD3'B3,YB5OTPDC!M&0_*GM_M]U8P7_-3,()0&2!258J14.[ M@U4'R0`,1DE12NPY\3NIL=_+HVSN;:?Q.2NZSP&[\UC]Q;KQSY&OW+#G\UBJ M.6AI,A7_`-YJG*7F2CE,3>/QAT50U]*VYF\T_>B^\;X$K2H:A!!;+ M$*TQX:Q!:&@J".I/_P!:3VCYCAB@ON4;=E12H*LZ.`:5.I6!+8'<:GY]7`_% MO^8"V_MT4'6?DQ69R)N$Q63Q^B2+&5M38>*99/#)( M=&E"5OD+]WS[YIYRWZSY#]T+>WM=]N6"6UY&"D,\IX0RQT(B=_P.&T,QTZ4J MM<;O>_[J2\J[+=_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[ MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_ M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBI?/#_LAWYE_^*I?(C_WT.\/=X_[1 M/M'3_=>ZU_?A)_P!Q`/\`._\`_$.?RU__`'RVYO=V^&/[/\IZ M;7XY/M_R+T43^<1\=JSY-_SP/Y073J]^?(/XRCL;H;YLX_"]O?&'L:KZJ[AQ M65V1L@;ZR>*VYO2DI*R;'4F8Q-"*?(QHA-10RR1M8-?W9*!22*@?LS3C_J\N MJN#K4`TK3/IACBO[.C5?\,&;F_[W8_SSO_2]MR?_`&-^]^(G^^5_G_GZWX;_ M`._F_P",_P#0/7O^&#-S?][L?YYW_I>VY/\`[&_?O$3_`'RO\_\`/U[PW_W\ MW_&?^@>O?\,&;F_[W8_SSO\`TO;(G^^5_G_GZ]X;_P"_F_XS_P!` M]>_X8,W-_P![L?YYW_I>VY/_`+&_?O$3_?*_S_S]>\-_]_-_QG_H'I9]&_R' M=A]3?*GX]?+?L'Y_?S(?E?OWXQY7?.7ZHV_\L/D33=S[0P-5V-LRNV1NP4%' MN#:/\5PR9?&5,$E1_#JNC-3-04IF,B0JGO32*5*B,#]O^?K8C(8,9":?Z7_( M*]6K?+SX\X/Y:?%KY#?&7<57%C<9WMT[V#U>TL*@,,J2*BNE@#Q'#CT0;^0_P#)#.?)#^6)\=YM]?Q: MG[>Z$QN3^*G=>*W"\TFY:I=@5%/N:2IDDK)=Q93:M!BLE6-.?.T]K.4H`N@3"5$TC3I44H,=%VP7:W6W MH%I6)M%`"-*T#1@A@"&\)HRP(J"2,TKT*_\`.$^6DOPE_EL_+3O_`!&;JL!O MO$=6Y;9?4V2QWADR]'V_VB\/7/6>3Q5+-',M94[=W9N:FRLD>AP*6AE=AH1B M"OVSY>_K/SSR[M3VXEM3<"25"&*O%%^H\;:<_JA?"%".YP*BO2C=[CZ?;[AA M(59AI#`JI75@N"V*QK63-<*<'ATO/Y8GQ+@^#?P%^+/Q@>BH*+<76G5&`3L/ M^&Z7I*SM;?\`F,\U\X;]OBRE M[:6;TQ-+G]G;\VOG]F;LP5<@DHLUMG=&)J\'GL M361GB2ER.+KI89%/U1R/88LKRYVZ]M-PLI3'>02I)&PXJZ,&5A\PP!'2N>"* MY@FMIT#0R(58'@584(_,&G5(_P#PGWW[N+"_$KM#X,=D[C?5_>? M;X#S#MG-EA!X>U[Y80W:+4'0[(H>-F&#(!X-! M*0:$FM2=3"N0OBB5%!\DP--.K8?E9\@MK_%'XT=\_)7>:>?;G1O4^^>S:^@6 M6.*HS4FT]OUV5Q^W:%YI(8CD]R9.GAH*56=0]34HMQ>_N..7-FFYBW[9]C@; M2]U<)'JH2$5F`9R`":(M7:@)HIP>C:\N/I;6>X"ZF5305`U-P5:F@!9J**FE M3T0'^11T%NCHG^6=T%E.RJZMS7=7R4AS_P`PN\MR9:DEH,_N+LOY-923LZ>K MW-23!9H=S8K:>7Q.+K]:HQJ<>Y*1D^-1E[N[S%NW/>[0VD8CVVPI9PQ@@K&E MO5'5*8\/QO%9*$T5@*M\10[);)!9"1:%IFUE@2VH$!48DDDDQJE37)ZM]]QG MT;](/LKJSK'N?9V5Z\[AZYV'VOU_G1"N;V-V5M#;^^MG9A:>59H%RNV=T8_* M87(""90Z":!]+`$6/M;M^Y;CM-TE]M5_-;7J@TDB=HW%10T="&%1@T.1CIJ6 M"&X4)/"KH"#1@"*@U!H:Y!R#Q!R.J4^U?^$W_P#++W;O(]J=';1[<^$?TOAKW'O#J#-8&N>G^WCGP&WI:G<6Q]MQ(H]<>*Q>/\H+:C=M7N4MK][^ M=[.W-ANKVNZ;6R!&ANX0RNH-:.T1B>0U/&5GX#R`'1//R_9RM')'))'(LOB` MU#T:E,>*)-`I44CT8+4(+$]!E'_+_P#YYWQ2HJ&3X?\`\VG:ORQVSC,K+5KT MS_,;ZEER]368SQ1LT-?\D=FR;U[BW!D9O`(XZ!N@D7Q&8A@>! M&`?$,S-1O))(%`.*4R+?Q3_G*[AJOD!M#X/_`,S;XR;D_E^?,C?TL=%U*F7S MU!OKXY_(NLD-)#3TG3W<.&DJL&FZ,A750IXL-45-7&*IX*%,C-DZB.@]E7,/ MM=#^Z+OFKD'?$WCEJ%2TM!IN(%!:IDC(5F5576S%(I`FJ0PB%&EZO:;VZR1V MN[6Y@N&95!H=)9E4@-\2J68E%*R2QLZZ!+XC"/J]KW$'0AZ__],,/Y4G_<7O M\\/_`!)?SZ_][2?W[K9Z^B/[]UKK3!_X6(=M])]7;`^`?^F#XH==?)O^+=C= MVU^%DWQO[N#K^KVEC]NX[J2?F, M,P$J^ZV*4->CB_S\?YW/=?\`)WV9\&FZ(Z6Z@["3Y'X'N"3,TG94N\OL=I4/ M4>*Z/.&H-NP[6W!@9I%KAVC,LKU,LFA*.,*MV8^_=:QY]4Q]C?\`"J+^E[(W]T+\DNW(&V]M?(U\6Z\[MG:E1U/W?U MCJEP^[=GYR.EQ<^ZM@YYJ.:`3ST%%44E9%)33PZ? M!/4^ZUU2U_PDB[7Z$W_N_P#FICJ'XG];?%N+:F^_C[59JKV/V'V]O.GS^`S% M=\E8L#@:J#M7>N[*';F(V*=LULU.<:E(:@Y>45.N.FHT@]UL^@'2#^:W_"K3 MOW>WR4SOQ@_DO_$FE^7M?LFHRD>9[1R'7_:W=G^D6/`5IQ^>R?5'4O2F5V[N M-NO\95R4XAW/6Y&:+(BHO'0P0_;U53[KW^'K6-_GA?S:ODG_`#)<+\6NK/F/ M\79/C#\FOB9E^^(^P<)%M[?.PL?GL7W-C^CZW:THZQ[.>NWYL7+XZ+KRJ:IA MK*ZMBJ8:JGFA=0SQI[KWEU],7^;Y\>-P_)7X!]X;.V7CWRN_-H8['=L[*Q<( MF:KRN9ZVK%W#6X;'0P*[5.6SNVH:^BHX2I$M541I=;AU%')NY1[7S#83SM2W M_YL70& MD>I:"6$/%-#("LD4L9*21RHP5D=&4@@@$'\>\CY+,,:Z:CJ>I=M#L'`QUGZM MR%%\A/D;U%U9DI!4XW>6^L319F`,UY\'1RR97.0AHK2*)XO.6W2^%NEGMLG@/0=EQ,5@@>C8)2:5&H002.!X$8\D;%%N/, M6SV,\>JW:6KC.40%W&,Y52/\HZWG^MMM[=CPT%(!!1TU'1QP4L$85(HHH(U2 M*)%%@J(H``'X'OAKR7M.UW%FYNG&NA-34DGU-34D\22>/4N4J2!POW5?0R26_`?W]!/L7SC<<_>T'M[S9>/JO[O;(O&/\4T0\ M&9OEKDC9J>5>N)/O%RM#R7[H<\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=%2^>'_`&0[\R__`!5+Y$?^^AWA[O'_`&B? M:.FY?[*3_2G_``=$T_D'_P#;G#^7K_XKSM__`-VF9]Z;B/L'^#K:<#]I_P`) MZMX]UZOU[W[KW7O?NO=:_OPD_P"X@'^=_P#^(<_EK_\`OEMS>[M\,?V?Y3TV MOQR?;_D7IG_GKY.L^.?9_P#*?_F/1145+M3X??.?#[#[RW37-'3T6Q?CK\N- MMS=,=J;VR]6\L)CQF%IS2TZB[`5=?"6`C\C+Y3AE/#_4/\O7G'[95^*WQ7^"]'V)\C\;C\#M?)4%9\F^W>P<;'U9M#/;G MJ,'5[GV]DJ/JAY,S0TE)D::*L2.K\\+^%";::+4C_5_J!ZIJJY`/#_-_LCJY M[W7J_6OI\""WQ+_G,?S1OA'6U]=#LWY4XC8G\T;H?"R0)'C8LAO[*U/5_P`I MLB:HG]S*YSM.'%""%>31XN1]/H<^YKYT9>9?:_V^YK1!]7MY?:KALU(C4/:H MHX:8X5UN>/B7`K\0Z#^WK):[KN5J[.8G)=*L",DN2`>X%FD9`*LH2`4T\.FS M^:?/_LU_\S?^4I_+AQV1>;:^W>RL[_,;^2V&3&KD:6/KOXXK5P]'8[<5+4JM M%D=J=F]G46:P-7$[,(9/#*T;D1V=]NE_JW[?^Y'/,D=)Y(!MUJVJE9)RIGT$ M=RR0A[>="*:@CKJI4%O=A]5N6U6.=`;6U4U+P;BQ(%#&DT3`5(,J$@8KL/>X M/Z$G7O?NO=:_M*9?AY_PH9R%//7R8[J_^;S\3!74-",=YH\O\L?@WCZ*G:): MU8W_`(104?QQR=5/(=4<=97U<:N&E\),U.RJQ6^.T-I#J)+:\`X.*JL80D9HSW!P#DY?Y]U9-WA MM+X/?RRL'D\Q29C^8U\PM@[,[%I<"9:?+#XK]&55!VQ\C=P8VO17B@KMM4U/ M@)1%(/'/%+(&]"L#OV80;3<\W\_31(T.Q[9(\98!E^JN`T=NCKYI,!+$6'PL MZ>9'6]_+3+8V"%P9I14A`U`I`#5;M#1NZ3"H-1$U%-,7\0004L$--30Q4]-3 MQ1P4]/!&D4$$$2".*&&*,+'%%%&H554`*!8>X59F9BS$EB:DGB3T(````!0# MJGGYM_,'MWX]?S1OY0O1F+WY'@/CU\O*OYD[*[>VF^V]IUJ;HWKL/K+8N5Z7 M=]TY;!5FZ-ORT^\]T".&'%5]"M:TI2H6=%55E#E'EC;-[]O_`'-W::Q+[QMJ M6;P2:G&@23.9AH5@C`P12DEU;3I!4J>)/N%W+;[AM,:W2I"[MK0TJZZ2@I45 M%)9(:D4]#\5#<7[B[HYZ][]U[KWOW7NJ6O\`A0'\;-C_`""_E:_)W<>=I5H. MP?C1L'.?)[I;L"@E;';KZ\["Z8H9=YC)[7SE.\5;C*G/8'%5>+F\;@M'5AUM M-%!)'*/L]S!=[%SUL\4)U6=Z_P!--&GVC_`'#L_P#K MM_U8^G?]P?UC^ET5.OZ?ZWPM&KXM7AXK6M<\>KUN_P!S5^I'UWTW]II%/$T? M'HK2FKNTUIY5Z__4"K^594TU)_PKS^>$M5404T7^DSY\KY*B6.&/4=Z5!"ZY M&5=1L;"_OW6SUM$?S[_YH/;/\K+X0X/Y(_'K;O4'8'86;[YV'U2N&[7IMRY[ M:E-A-S;8W_N+)Y,XO9&]-CYN?)0MLZ**$_Q!(4$S,Z/8#W[KW6HE_P`*8/E! MO7YI_P`LS^1Y\J>Q\'M;;6^N\-N?(K>^Z<%LFGRU)M/&Y>LH.F*6I@P%+GG*K9=33?W(I.KL?M^D@VS'BIQ(8H,?0 MX6"-'$K"6-D836D#^_=;-:YX]:'W_"=`=>UW_"D7^9CEOBQ_"JGXR'8GR\_N MKD=K+1S;%DZ[R'RGZDGV0-H5=!Y<5_=VNK::&7`^!@9.>B M^_\`"?4[U'P,_P"%0AZY.8&^!\7<0=LG;IK!N(9,=:?/?Q';QQW^Y(9\)J^R M^V_RG[KQ^+]S3[]U[SQQZM1_X1*UO0R_$;Y;X_%U.SE^3TWR/AJ]\4B20+O^ M;H>#K'8$75-151.14S;/I^P)]YK3F.Z1ULD_DL7BO[KWET37_A;[7]'5'9?P M,HL16;=G^1M!L_NK^_=+C*C&R;HHNGZG+;!DZW_OC!$YRE/BJG=Z[E;`>4") MI%RI3G5[]U[RZ^AS[]UKK1S_`.%#?\I7H[IXY;YF=&]K;9ZBW1V5N2&#-?&W M)XS(U-/V3O')UL$FXMU]85F-FK)=N3P4LTE?EJ.II!BC(2Z5--)+'3S3G[=\ MV[A>Z-EO;5IHHDQ,".Q0,+)7XO12#J^1`)$U<@]M7FCC3$P/P*." MN#QSA2#J]00"1K(_&ZJW'T1\E^C^V=Q5TT6&VAO_``M7N&=H2L5/M_(2-A\_ M.5B$LNB#$9*=N`[6'T/T]M_>!Y0N/<;V3]RN3-J@,NZW>URFW0$5>XAI/;J* MD"K31(HJ0,\1QZGOD[>K3:^9=HO9F"VZS`.UVYV;&*"& M2EK(IH)H(Y89H9$DBEBE4-'+&Z*ZNDB$$$&Q'Y]_-OMW.4M@CP2%HY4)#*PH M01@@@@$$&H(/`\1UE-N/**7,HD"!E.:CA_AITC-X[X%:DA,H8M?^U?\`!M_9 M_K_7GV%.9.:/JPY:3H2>1PJJ,DDFB@`<220`/7J9MLACL M[=IYV"01H69C@``5))]`!4UZVJ_C3L*KZRZ$ZIV1D$:+)X79N*_BT+J%>GR^ M1C.6RE*X#-=J2OKI(KWYT7]_0[[$\GW'(7L][=\J7JE=PM=LB,RD4*S2CQI4 M/^DDD9/GIKUPV]Y>:8.=/=+GKF6T8-97.X2^$1P:*,^%$P_TZ(K?GT./N6>H MSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=> MZ][]U[KWOW7NO>_=>Z][]U[HJ7SP_P"R'?F7_P"*I?(C_P!]#O#W>/\`M$^T M=-R_V4G^E/\`@Z)I_(/_`.W.'\O7_P`5YV__`.[3,^]-Q'V#_!UM.!^T_P"$ M]6\>Z]7Z][]U[KWOW7NM?WX2?]Q`/\[_`/\`$.?RU_\`WRVYO=V^&/[/\IZ; M7XY/M_R+U;O\N/C#UG\T/C1W7\6>X:#[[KSN[869V3FY8J>CJA_(]4E_RP M/YA&Z_B_NO"_R@OYHN>@ZU^7G2E!3;1^.G>>[*FJH>JOG+T=C#)0]>[RV%OC M,B.A'96*PE/!C.2>O\`XA2T=V!)U#S_`-1_V1^S'54(4:3B MF,_RSY_(_D<];'_MOISKWOW7NJF?YD'\VOI+X)4F/ZCV?15'R-^=O::P;>^. MOPSZP9MP=E[ZWKGHI(=L5N\J3%&>3K_KN*JM45^3KO%*]##,U'%4R(RK8*:` MD8_U?ZCZ=5+`5%<_ZO\`4/7J'_)_^`.__A5TOV7V%\E-S8WL3YR_,KLW(_(? MY@=AXU8GH3OG/"IFP/5NW*J%FAEV1U-0Y*II,>D.FD6JK*UZ5(Z62"&/;MJH M!P'^K_5]F<]:1--3YG_5_A)/RK08IU;E[IU?K7T_G+5TGQ8^4O\`*C_F84,] M31X+I?Y/5WQ+^0*TL4L%#/T!\Q`ZDW/MR.NHJ29#%-ELI M"P*2*C":O:V/^L7+_N%R&PU375B+JWX$^/;.I6.-3^.=FB#LI#+%&^&!*D.; MXZ64^W[F2@"/1B0WP@,S$LM0`L7CT##279>Y32O'^54_^S:?S$?YKW\R.KJZ M[)[0H^V\'_+M^-/\1CU18CK#XP8W&5G;>9VG6F25*S9':W:V5ILW2>+2$JXZ MKR?N,T4'O<2O+?)'M[R*BA;AK<[C=4QJEG+B$.*`^+`IFA8GB@33VC4]]L6* M\W"\W0!25K&I#:J*V@D4_"&1(7H*98FE_=>ZHN_G];8W'M+X MF]5?.;KRER55V7_+8^4'2ORXQV.P=*9=1DLPU]$E%ABC^@D^Y>]F;BWN.9-PY3W"54V[>[">U9F/;&^@O'+IH=4BZ7 M2(4J'D!7('1#O\3?2Q7<2J9X9%*UU9)9=*U3*J91&7)!70K!A0D@,?BWN#`? M/W^=YWY\OMK5CY_H/X&_$?I[XU]'9M*AJ[;6[NW/D_BD[][([#VP3I3%9S;/ M7&>H]K9:'3KD2:!BQ`4`QYC@N>2?:K:^5;J,Q[UNNY3SW"T`=(K9EA6%_-D9 MXXIXFP`?$`!-2$ME)!NV\G<861[:.%2A&LUU!@C"M$4C5<(X`+$>&20*#K8? M]PAT*.J:/YWGPD[>^7/Q.BJWCIS)+'*7M/S;MW+._7EGOP)Y:W2 MU>UN15@JK)@2,%920`7B=JZDBFE9`6`!)-\L)+RWBD@`^IB<,#12:5!.DLCT M9&"2H-)U21(IH"2!1_EB_P`UWX[_`,S#JV/);-K1UK\B]DT@Q?R$^+&]:K^' M=J=.;YQ4[8K<@D2@S4--&LD3)%704&26IQ],7\^^W.]\ MBWQ^H0S[%*:V]T@K'(ARH8BHCET_%&QS0M&TD121E5CN5O>@(&I<4KI.*@4J MR_Q+D9!-*@-1L=6C>X]Z,>O>_=>ZUE?YR_S/A^8$C?R3O@)G:#MOY7_*'(8[ M:?R.W9M2^>ZZ^(WQQI,SBI^T=W=L[KQDLN.H\]7T31X]L+`9ZV.AJ*A)Q35] M5A:7)S][7\HMRW'+[I(5!O7_V5/J?_`&3_`/V1 M_P"US'^@S_9;/]E3^R^_A_C_`/HG_P!%_P#HB^U_BGV?V_\`&/[G^C[C[?1Y MO7X[>GW$G]:-T_K;_76J?OK]X_6_#V>/XWC_``U^'Q/PUX8KY]&_T$?[M_=G MBR>#X'A:M1\2FG1JU\==,ZN.K/7_U5Y\W/\`A(U\D_D[\U_DU\K-A_-'J?8& M.[V[O[([:P>$KME;].X]LTG8&X,CFVP]7E<-D8H)ZBCCR3P/)"565!]`"1[] MUNO18LI_PBO^9&0ITJ$22))TAJ\M-&LRQS M.H8#4%8B]B??NM=6W?.C_A-CV]\M/Y??\LOX:;>^376^T-S?`[:O8&VMT[US M.RMSU^"WZ=]0[0#5FW\90U\>0QG\.FVN;)4NWD67]2D<^ZWU6Q_PM^QK8;!? MRH<0\JSOBL3\R,:TRJ469J&C^(-*TJJ22JR&*X!^E_?NM=<-Z?\`"53^;-UR MVY/C3\6_YG3T_P`$MZ9;+RY+8FYNV>]^MZ`8+-5=2U70[PZ-V1%G>M=XY*>C MG"U\L=12TV4F7RO!#=8X]=6!X9ZVE/Y/'\G'H;^4%TAF]B]?9FH[.[B[)FQ6 M1[K[TS&%BP&5WQ681:X8+!X7`1Y',KM39&VOXG4_98\5E5(9:B6:>:662Z[Z MU7RZ+#_(N_DG;\_E)Y[YOY+L3NG8_=6.^6&=ZFK,+C]L[5S6"_NWBNMJSNV> MJI\__&ZJJAR4V;@[9B31"HCC^T>Y82`+[KQZJ$^8O_"4+Y`=;_)+/?)W^35\ MM4^*]7N.LKJNFZQK=\=F]29+K7^.UOGS^$Z[[BZQ&;W#-L&J708<+742M31Q M>$U51$8UB]U[HM^\O^$:7S![GQ&'[.[I_F,;9WQ\FMWYO+9#N+<._L/V5V;1 M3XY<;MVCVO'C^P]QYH;XWEN"BDI:]:VJR,-+"].:2*&-/#))+[KV/4];H7RH M_F5_![X72OCOD1\A]A[+W0E/'5G85'72;H[#%),"T-7)L?;$66W+2TDX!\AJV[;I'B_CII3_>C1?Y]'6U\N;UO(U;?M[O%7XB-* M?[T:#]AZT[OG-\K]E?S*?E[D.T>O=Q5^?Z)V_M_`[/Z9?+XO*[?D_@L.-I:W M=&6GP&=IZ+(XVLS&\JFM+>6&.1Z:"GO<(I]S9RYL\W+>S+;7,06_9BTE"#FI MTBHJ"`H'KFOKU+&T;9-RWM*VL\86^9BTE"#FM%%14$!:?G7HA'R,Z?PFV\?/ M'":9V$%]411AS_32;'Z>Q)8W32$'/'H\VR^EE8%O7IJ^+O\`-23I!,=TQWI2 M;@SVU\>4Q^S][X&FES6>Q5'JBIJ/`YG#1LM7EJ"D`M3ST_DJE4Z#'(`NGF7] M[/\`N^KKW`WGW2GPH)Y22S3V\N1%+(3^I&X6(GO#(2U M2RC%(YE!9T7R1U&64`889`P:CH=.^_YH&\*.MJZ#H_ MKRAS6(@&E=V;W&5@2M8*-E"RQQE0302&E2(.8/O$V5G>/:\I;3' M-;KCQI]0U>NF-2#3T+,"?X<](#X?_P`]27H7Y![4W;\L?CGA.P^O\;D%:2KZ M^R.0Q.X=KS.Q5-R4N`S]3D<1NVIQ1(>.DDJ<>-0U"0L%4S]RC_=D>SWM[S;8 M<\[1S'NNX75F"T-O?>!)`)\:)3X44;U3)4'6`^EJ=O4:>Y/O;SSSGR3N7*]@ MUMMXN1IDEB#ZVC_%$:LVA7X,Z@MIJM,D]?17^,WR9Z4^7_2NR/D%\?=[XW?W M6&_L<*[#YF@;15455$?%D]O[@QKG[S`[GP%:&IJ^@J%2>EJ$96'T)F>_L+K; M+N6RO(BDZ'/H?0@^8/D1USPOK&YVZYDM+N/3,I^T$>1!X$'R(Z'"KK*3'TL] M;7U5-0T=+&TU35U<\5-2T\2"[2SU$S)%%&H^K,0![1]).DO@>Q.O]U5_=>Z6/OW7NO>_=>Z][]U[ MIJP^=P>X::2MP&9Q6)*JFD],D9(=& MX(!]^Z]TZ^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U M[I#=G]>[>[;ZU[#ZIW:*T[4[.V-NWKW*4HXCDLVDVM[V"001Q'6F`8%3P(Z#OXM?&[KGX@?'KJ;XR]1G/GK7IC: M-'LO9QW3E(LUN%L/135$\39?*PT6.BKJQI*EBSK!$#Q91[\34UZ\HTBG0^^] M=;Z][]U[KWOW7NBJ];_#KI_JOY5?)3YB[6_O5_I@^5FW>G-L=J#)9N*LVK_# M>C-NU^V-D-MO"+CX)L/4MB\BXK6:HG%1(JLJQ\@[+5`'IU4*`S-7C_J_R=&J M]ZZMT5/Y??![XH_/7J^7I_Y;=);.[GV2L\E;AX]P4]51;DVCE)1$DN;V'O?! M56*WGL3-S10+%+58FOHYJBGU03-)`[QML$C[.M$`]5,[>_DC_)'H&HJZ+X3_ M`,Z3Y^]&;$*_;[?ZQ[I3KOY@[$V-BDD+T>W=C87MG&X^GV]M_%1D0TT2!ZGP MJ!-/-(6D:VL&NI?]7VFI_GU30PII;_5]@('\NI^X?Y0G\P+N&GBP?R*_GV_- M_/;3-0LM;0?&OJSI+X=[EJX0"CTIWEU;19'(?;S1,5>*6&:![^N-AQ[]J45T MK^VA_P`G6M#FFIQ^51_S]T>OX/\`\J/X,_R]Y-1DL]04NX*RG2IKL?BCC<34U@-0U+YV>1M,[- MQ./]7[?SZLJ*O`9_U?LKYTZL8]UZOU[W[KW1:?F%\3^H_G'\;>TOBMWK2YRK MZL[(QNYAMG*)A-Q4DNW=SX/>>WLMA,I+1Y""CRF$W1MNBK(&EIYX3)`!) M&Z%E(@Y6YEW+D_?]NYCV@I^\+9F*ZP2I#HT;!@"K49'855E85JK!@"$M[:)? M6TEJ\KHK4[D-&!4A@14$'(%0P*L*JP*D@P/A=\/^GO@9\;.N?BMT/%N->LNL MEW.^%J=XY>'<&[,G7;QWAG]\[ARFX^)64P-E-H;\V[D=K;EQRSJ&:$UN&RLT08`E=5_:[:]QNMGW/;MWL7 M"WMK/'-&2*T>)PZ&GG1E!ITU/"MQ!-;N6".A4D$@@,*&A&0=WAN#$;=V]4UM=DJ/% M8/'0TU)M_:6.HZ>"FHZ>)(Z8.P::26602<\<\[W[@;Q'O>^B%;E(%B58E8*$ M4LP^-Y'8EG8EG=C0A11%50EVZP3;H&A6>20EBQ9]-22`."*B@`#@JC-2:L22 M>_V#>E_7O?NO=5,?-+^2E\#?F[OR'NW=^QMU]*?)BBE2KQGRC^,>\*SI;O*F MR<5+3T--FW=WYVBH:2&GI\AG,7DZZEI8E@@FBANAD;ECW3YNY7M! MM<%U'=[)I*_37*^+$%-:JN5=$JS,8T=8V8EF1B>BR[VFTNSJ8%'U*Q*TSI.K M(8,N3Q8`/@48$"A7=O\`\I/^95U72G"='?S]OEGC-M1U$TU+!\A.@^HOE=NF M))G+>*HWMV?G8,O5)&ILJZ4C3^PBCCV(YOT%F]P%`K:W/T2&GG MHBMB*^I))/F2>BW]T[U'*[VV^*(V)-'CED/Y$W(`'R"@>@'4'-_R2?E!WO5P MT_S1_G5_/7NG9CTTM#G.O.C*;9/Q`V9N_&3R++58;=V`ZY;4_:_;+2Y5PRR7#?62(PX%)#%#*A'$:9`*T)!Z\ MNQWLYE_>6[>*CH5(1'1:'^@\TT9(]2A].!(ZM4^&GP#^(7\OWKZHZU^)'1^T MNH\'E'IYMSY?'K79O?6^*NCGR-515>_.P]RUF8WMO%\9/F*O[&.OKIZ?&Q5# MPT<=/!:(1SS-SCS)SA=)=\P[I).R5T)A8XZA5.B)`J*6"+K8+KD*AI&9L]'= MM96UH7:&("1@`S<68"I`)XT!9B%^%=1H!4]'#]AGI5U__];?X]^Z]U[W[KW7 MO?NO=5M_S"_Y3GPJ_FB0]20_,'86Y=Z_Z$)-]2==R;;W]NO8LV*_TCKM!=VI M52;7R-`]^Z]U[W[KW56O\` M-M^?83=U]JYUM@=6QUT:U4.%J&QU3D-P;XJ,>Q5:ZEVK01QJ MB$Z#7UM*'#(64BSD[8$W[=/#N*BQA77)3SS0+7R+'^0/0FY4V5-ZW+1<5%G$ MNMZ>>:!:_P!(_P`@>OGT=B=+[MWU5YS?^_1V:P`_'O(JWN(K=8X($5(5%`J@``>@`X?EU/%M M?P0>';P((X5P`!0#[`,#H,>NNQ9^H*Y=O2N:9:(O]J2SQAHB\C66Q`]+L0;? M3CVIG@%R"X\_]7^K_B^E5U;"]7Q`*UZ&W)YSN'Y!4U31=9[`WEOV2)/%/4[? MPV0KZ"E>Q(2MRFD8VB)_`EF2_N.>NA&IT; M>TL'C:5#BLCF<))-AY,E6U!1)3E:4UF-BJ*6FADM&TBR7<,!Q[0$]E?< M.7]UQW'> MLTVCTZB>')$P;.. MAO9/XL+(W`KUL;?\(^/EGNK:_P`F._OA9EY_Y3\ORCF^*7Q?Z\[$WSTKAMNS9/,X_9^XJWK'!97,;OWKNS8B[JVO1 M=R=E[RR^*J:7;U)554%-38LPK2"(O73UD-]1+3_!T9+Y'_\`".?NKX^[73NK M^6E\V]_9CY`=?TG\9P6S=W14_3FZ]R96B--4$==]U;(W/BH-D[B8PR?8P9&F MCI):AHEFR=(BM,?=>^SKRL+%]K6;FK8<;-F_M&R,]'1R3O3Q^Z] MUKT=X_\`"S?^6]UQV-5[-ZKZA^27?NUL1E109+M';V#V=L?:N7I%6)ILIL;% M;WW1C]XYNGB+M&%RN.P)DDC)0F(I*WNO4'KU<)\7?YJ_P>_FG?#KY#]E_'CL M[?V-Q6R>K]YT'=.R/M*38_R2Z7I,UL'-Y!,E'@TR^2QT&7EQD-6V"SF,R.0P M53E:">&"NDFHZI(?=:ZJB_X2)XCXRXOX??*:3XR=K?)#L_;M7\H)I-R2?(;K M+9'4$N%R@Z^VQ-C%VQL[87>'?.'JYZ[`U,`RV8ERE%49"IIXXS10Q4T+2>ZV M37SZ&3Y\?\*LOY\,]B(\OG,54&2&1<)C\O1Q55/-3SU,$T;)[]U[\^CH?RO/Y\'P0_ MFN5N3V3T=GMX]>=Y8#"/N'-]$=R8?%;=WS482D-/!D]P[.K\%G-R;4WQM^@K M9],C45?_`!*FA*35E%2)*E_=>ITE_G5_PH*^!O\`+I^6^`^'_P`F,?WGA-V9 MGK[%=EU_9FVMC;5W%U-M?;69@W/+CQG*M.P:3L6KRM1)M6:%*7%;;R4LD\\$ M<>MG.CW6NJW^I/\`A95_+3[&[LQ_6^[.KODIT[USG\U08/"]W;YP&P:W;F): MK8Q/FNP]M;2WUG]P[5VY%/9?N,>,Y,J.))H8(Q(T?NM_GUM,]D=T=3]0=3[G M[U[,["VILWI[9VU)=\;C[&S69HZ?:F.VK'2I61YG^+"1Z>JIJV*:,4HA,CUD MDL<<"R22(K>ZUUJ>]H?\+2?YPY-L]==$_*7MO8V/R4]#D>S*'!;`V71Y M2EAJ&C7,;*VINS>M+N7*XZJIP)(DS,>W:NY*R01VN?=;QUL._P`OO^91\2_Y MFO3+]U?%7?\`+N#%XJHIL;OK9&YJ*+;W9?5^>JZ>2IAP6_\`:HK*]<94SPPR M&GJZ6HK<77+%(U)5SK&[#W6NJ8OF[_PK4_EL_$GLW<73W7^&[6^6.\MH9-\1 MN?<'3=/M*CZEQF5HZDT^6Q%)V+N?<5#)N;)8UE(,N'QF0Q MO5AW\KS^>%\&/YL<.X<%\>]R;KV;W%LW"Q;CW;T+W!B<5MCLNCVX]><5+NO; MR8;.[DVSOC:E-DC%'456)R-5-C?O*,9*"ADK::.3W6N@M_FK?\*"OA#_`"G] MW8?J/M*B[([?[]SNW*#=T/4?46)P]14;;VUEYLM3X7.;]W=N?,X';>VZ;+5& M%G6&DIY,CF1&8IWH5I9HJAO=;IZ]!5_+7_X4T?R_?YD/;FU?CK@,/W%T1\@- M[&KI]E[&[5VQC*_;V^ZV*??NM=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]??X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW6J9_P`*0WJ![;>-/\`:UC_`&4?_+U2=NOL M'9M1L*.BAAI4JDIV#2@IJ;T-8&[V'^V]R#%!*L^HGMKT*X;:9;BI;MKT6[XF M?#&C^;7R%EH]9CI9:2IRF>.TU`.+>*/3X]VR5SX8=4A##29 MG5B&6-U,V^WW+D6Z2SWVY`_NBV`+^6MVKHC!^>DLU,A00*%@1MBX+H#:W7.S M,3MC9NVL=MK;>%H8:/%XG%44='1TU-!&D:!4BB&MRJ`N[$NYY8D\^^)7-/+V M][[;Q=.9)9YF:261V-269JDU)P,`#"@``=3WMG-L,B^;[V['3&9/&NGU(R%;JPL05(TD%2!:Q'O';F"PEVVX M%Q:RO%<1M574E64C(*D4(/H0:]3=R_N"7L0CF4-$XH00""#Z@X/5-GSAH:OJ M_:B;UP2M3[5J,DF)SF-@#?:XBOK4G>@KH(D58Z/%UKPF)@2$CJ&C5`!(JCLG M_=X_>LWCW8-][/\`N/N1N>=MNM#/9W^OLWMW+4]OS?RU:B+:+F71-$H[8I2"0R`"BQO0BE:*Q`6@(`UJN]^ MPHMP5DZQRJ^N1W8@C@:K\V8VN??6-=-K`[-C'4'HJVELTCG@,=;)7_"/7XQ[ MIWG\O.^OEQ78G*4_7G4/5-;U7@\^U+418G+]E=BY7!5]9AZ6N:+[2LJMO[+Q M,L]9`K^6`9*C=ETRJ3"'N#N4?T1M0P,LTRGB*A$#$XX@%BE#P-&`X'J%^>-P M3Z&2W!'BS3+3(KI0,6J*U%69*$BAHP'`]7$_S>O^$O\`\=_YD/R%W;\B>D_D M`_QM^3>\\?@A.V=JXKJW.83'/D+STD;YOPP(TC1:%) M'NO<:YZ5/\PK^<7\E?GE_P`)F^MMZ[^K<3C>Q][?//$?#CY-[CVS@8<#CNSL M3UAU;7?(+!92+&TTLM#MZOW954VUZW+I0+24DU?05<=-3TU#-]JGNO?8.MJ7 M^1__`"T_@_TY_*Y^*]=@^A.J-^;@^3GQHZC[?[WWQV!LG9^_]Q=D[D[AZWP6 M\=S;;SF8SN!FEJNO]NU.X9\9BL&R+14=%&?)$]7/65%1[KQ)!H#T('7W\H/X M$?RX.FOGCV;\4.FAL??/=?1_=<>YMP9/<6;W+58/:51M3/Y^'K;8T67JYJ7: M'7]'F8HZ@45*@FJ'@IQ535"TE(L'NO5\NM4?^03V_P!@="?\)X?YU';G5=57 M8WL/9N6[#JMIYS%B;^)[8RN1Z!VAA(]WXUX%=H0%%8 M>_=:ZK'_`)&'RF^8'POZ][2[,^*?\EO<_P`^<]V!O"3;.1^3>/Z-[P[0?9^% MP6%PT]1TUMC<.P>O]V8';$2UN2_BV9@IJFGJ\F:N@^^22.BH#'[K?2LS6V_Y MGNZ?YKO1G\Q_I_\`DL?,+X5Y_;W:W6F\^R]H=&?%?Y1TVSMUY2FW1/2]K;FD MI,EUUCL?M^/M?KO)S8G<=!21T^.R:R5=54J]1D*V27W7O/JRO^=QT+UY\G_^ M%3OP@Z$[:QLN;ZR[+VK\5L)OS`15$U(-Q[6@WIV-EOPOV+_*6SW;W5WQJZ6ZB[!^/F M_NF:'KOZ]D@]4P?SB/D+V[3?\)J/Y)'5E/EMQ#9W;NW-NTG8N4H:VHH\=E<)\ M?]D+A^K.O=QQTLL,.4Q"I609"EI9TDB^ZVS3U%O-3QN/=>\CUN5?RV/Y8/P( MZ+_E_P#1W5.T?CST3V+MCLWHOKS/=K[QW9U[M3L&I[]S.]=F8[.;DW5O7,;L MQ67J]TX;<=;FJB6AH:AGQV.Q\T=)1P04L<<*^Z]P/5:GSY^`?Q;_`)(7\GC^ M9WVO_+TZKRFQ>T.U^NJ'96Y=\Y/=F[MX;WQ>S.XNVMO=85V+VSGZ[(RY';.$ MZMV=VAD*C#O2F.HADH(*RNJ*JJB>J;76QD]:GW\D3Y=_-+X4=%;QW+\4_P"2 M'O'YPS=I;QRPSGRFINB.].S&J<9AZ2BQ`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`PJK#((]0>MC_`/D);FP^5^.N_=U:HGRN3[ISE#DI3H:?PXS; M&U&H$D:VL+HK7*@_2Y/Y]\:?O[;M):_>'V>WN36UAY=M?#!X4:XO"]/++#-/ M05X#K('DO;3+R.X@&6NY2:>H6,?RZV&]P;VQ]5A(Z4+"IBBTZETW8<*/ M.-Y'(\A4]9,=>;S^.W4U/B:OLOLK&&@V1#F\C'B, M4^X<35T^XZ(5F4DBFBQ\+'#D&5E*I>YL+D#7[EG,D_+/WL/:3=(&?PC>RQ2A M?.&6VF22H'$!26(_HUX]+_>F2QL_:#G"_P!R-+:W@60&E:,LJ::#C4D@?GT2 M/X[_`/"1CYS]D;RH)OE)VKU'T=UW3Y&D?/KM+/5?9_868QBSDUM+MZDH<=1; M6Q]544T>A*FLKV$#2*_V\VEHS]*6\>Y>TO%2T2::3/;IT+\JL3JX\0$]1J%: MCD_N_N+M4D=+?QIGSVA="?*K$ZN/$!,@4#`FHWQ_AU\.^AO@ET)L_P".7QTV MA#M+K_:<N],RD$$N?W9GGID-35.J@1QQPQ+'3PP MQ)#6X[C=;I=/=W3U0%3ZDDDDDDDQ#N.X7.YW+75RW=P`'PJODJ MC-`*D^9))9B6))TX?YIW\G'^=WTU\_.Q_P"9;_+2^3_:7=N?[&R-1#'M^D[& MQVW>Y^M]E5M?'ETZT/C]_PKC_`)JV$Q_Q=^2V-WEUSTAN/(T*;YKM\8OH[X^];55+#/%51UG8 MLO5.&H]_;ZP=#44J3_PNEHK^SK72Z3Z^_P"%:G\JC:&;^&7Q^ZH'>?2NV/#[EH5HJ&=IBM%&'D9_=>\O+J[S^ M3Y_+Q_FP],_&3YO[Z_F(?)3L+LWM?Y9=:[_&Q_B[N'L=>Q<=U[O7=>VMP2Y3 M=F=W!55E;M7;6^-UY;)0X]<1MFHCP-!0PAIIJEW@BQONO'TKTBO^$U7\KWY` M?'#^7[\V/BY_,&Z!R/7.-^1O:&Y,/DMA;BS^TLVV\.J]W],;?V#N5Q5[*W%N M*DI*:O62LI06FCG5D+JH&EC[K7#JIK9/\O+_`(4,?R$NZ>W]N_RRL!0_+[XE M=LY^;.8C#5U'M_>V*=J/_(=MYS?76F0W#L3VJ'!RI19+([;G_A69AI8# M4O*E-1T]'[K?5FG\J_XE?S_?D!\[L)_,&_F9_(C?/QLZQVO25>$A^(FTMTT. M)PG9F#AQ68&`VQD^H-HY/.=<[:V/CJ.N M?SM_EO\`S4[9_P"%+'PB^;G7W1N8W'\6>LL+T?%OSMV#<>R:7$;;J-FY'LFI MW!3U>$K]RTF[:B6CBR]+8T^/F20SJ%)L^GW7AU:'_P`*(OBSWW\R_P"55WET M'\:.O*_M/M[J)NGJ7_A7Y_+UZU?X3]4=0Y+MSKC8=/)L?J'LF7#]5]T4FR]IT?\`D6#I M^LNPMTY_'5U/LK%4FB/#8_=M#*F%H(XJ2&DHZ6GBIHO=>_9U?5_*%_E1?-K: MGPL^4_4G\VWY*=B=ZP_-G:VZ,!GOCYG^R*_LNCZ2Q?85-NA-]9C'[YS39<8S ML[=.0W(Z\3U1;U?\'_`/A1]_(8[`[5ZI_EZ;.P M/S#^*G8^Y7W=@U.%P>]-LG+M1TV-IMQY7K^OW=LK?'7O8S86EIZ++/C:B3$9 M):*`O)4""G\/NO>75JO\H7X>?SXNS_FGE?Y@G\T'Y-]E](;&FH:S'4?PRV[O M:A&U=^PKC\GCMN8S/]2;8KLWU9L#8^SVKQ5TL]ZC=E=5ES//`TM3/4^Z]TE? MYCFS?^%-GQ@^>G8GRN^#>^,;\N_C1V-34V$VG\;HH,57[,ZKVGBGEEQ6W\_T MQN/<6UJC^]4<[M)4;NVQDVRV9,NBL>&FC@HX?=>Z)_\`%_\`EM_SA_YJ?\U7 MXX?S#?YKG3FR_BWL+XDY'K;<>WMO8+![Q\'M>FW#O[= ME70578%0:O-9'<5@(,L0B]U[K?-]^ZUU[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__1W^/? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1&/E1_+0^"/S M8J(")#9$>M94_L@>SS M:^9-\V8%=MW*2./^'#+_`+RX9?Y='6V\Q;WLZE-NW!XX_P"'#+_O+AE_ET1+ M??\`*Y^.?P=ZGJLE\'^I*WK?:<6X*OTZ;?'9784F1>LH<=C8MV4]5V7O M/>F9I/X3!C8X:B"DD6$P/YF1?%(YP0^_%R5S/SC8;-[J;>)+K<=I@-O=(B*& M^C+F1)0J`$B"1Y-=%8Z)2Y(2(]9=?=E]UQ-N]YR)SAN">#>L'M)'"H!.,-"2 MJJ/UEH4+$=Z:!5I`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`"L.E-O92FRF]-S[L["6FE248BH%+M["U)0A@E9# MCVJ,E-$Q'(6KCN./81Y/_N]_:S9;^"_YJY@W'>A&P/@MHMH&IY.L9:5@?,"9 M<8Z$_-'WW_MF]F[9W!W7TGCML9?M7KB@ MJ)VW'LG&[SIGK-L5N7IY:>.$09>F36ABDDTAEUZ=:W-;G9-UL]ML-XN;%TVR MZ+"*0TTN4)#4S7!!&0*T-*T/2.'<+.XNKFSAG#7,)HZT.#132M*$@,I(!)`9 M:TU"L3J+Y/\`0'?>\.YM@].=J;6["WC\>=YKUWW5@=NU-14U?7>]F?)1_P!W M,\TM-#3KD5FPU7&PA>54DIY$8AD(%MQV'=]HMMMO-RL'AMKR/Q(6:GZB44ZA M0D@4=3D`D,#P(ZK:[E97TMU!:W`>6%J.`#@ZF7B0`>Y'4E:@,C+6JD`>?91T MNZ][]U[KWOW7NFZFR^)K*_)8JCRF.JLIAOL_XQC::MIIZ_%?Q&%JG'_Q*CBE M:HH?OJ=3)#Y57RH"RW'/N[12*D5?*O3C[IU?I+[WWKM7K;9>[^Q=]9RBVSLC8.U\_O7>.Y,DSICMO[5V MMB:O.[ASF0>-))$HL3B*":>4JK,(XS8$\>U%I:7%_=VUC9PF2[FD6-%'%GF[:G9G7^^-J=>[WVIN_`Y MC:O;.!PFY^MAH:&GGK*VMK)XJ:DHZ2FB::IJJJIF9(:>GI MX49W=V"HH))`'M*JL[*B*2Y-`!DDG@`/,GI]F559F8!0*DG@!ZGJ#-GL'3X4 M[DJ,SB8-NB@3*G/39&CBPHQ2.4>9:$4$D#AUF\GC*$$&QO[L(9FE\! M8F,]:::'57TIQK\N/53)&(_%,B^%2M:BE/6O"GSZ6UN7@ENDM MY#;(0&<*2JD\`S4H"?($YZ::>!94@:9!.P)"DC40.)`XD#SIPZ4?MCIWH/.S M>V.N>FMO4&[.T-VXK9>W,IN_9&P(V-L;`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`EGI'U/&P=WCE3E+9;3>=X3 M8A/#'L>VW212/J]M;NPG5OR=[N^._4O:FYMU=F===@;>DSD$O3-1)6[0VA ML^E2MJY1-/6X^FDAA=5-R/RU9;S[Y@N;6:1GN0;>**>*)8_P!"6-0WAN9B\@-1P[0>K0X M.T/D7_)6ZKS/8.%Z7Z:R^Y8]M?*WXM;SWQW1+/\`QG94]-GLGE=P8V.?%RY$ M52832(:-(Z4R4TCB\H\L0[?]3=;6T\-O9;Y,L;3SA-5G>1QP`:9`5`0D-IIK M^)ZM0A,.8MY>^,*7GAM-<[9&76.'5_C-L[.26C8-W@-0@T`*H4!J!/ZB^:'R MNW;WUM3XI]H_,7(]:;7P_P`O/YE_565^4E;UU\<<-OCL;&?%-.AJOICI^JCW M!UA)TCMSWHVL-WW.[D>QN^8A;^#N5U!X MFB`23+"BE1WJ8U(K5RL7=@`IP(W;+[T[-^1/\B?YT=C=M=F0=Q[M@Z;_`)IN MP(.S*?"[*P$.\-I=69[Y&=<;$S"8_KO#X'9Q%1LW;%"?/0TJ1U/^=)=G+L4S M[38;+[O1V?\3/Y#^&Z>WOL#+_Q_JO:F MSNQ5I,9U_O[*8*KV=_*^[2W[C<9'79/'Y[)[!W!1;JVC2O.]%)05TU/%+23, M]+-/#(OO-B2ZYE]W)=RM)E`NG>.IDC#!]TC0M0%1(I5C34&4$AA1@I"6RO&B MV'D]+>9/%BLUUBB,5=+8#2=0)0@DUII;%"=-02X[=^?_`,KE^-/Q)[.;Y@8K MY+[G^47PF^:^^^Z^J:_K3XU38;JK, MF25E)>-C(CQ!'316I&0'_P"L>])MNTW)WGZF6ZL;MI8FC@/A-%`[JU$C4C2X M".LE58FFD''0??)KY1=V]\_"7YP;2['^3>/Z)VSU3_+5^$VZ]F=18G9/0^"Q M7R!R'R"^/E'OOLC=M4=R['EW/3X3(;R>3:F*QNSJS"TN(J*&2R2/+#%&LV'E M_:MFYLY4NK'83=SW&^WZ/,SW#&V%MV306"4F=IU8+O-"KO2L>L5>L:B)E"^0K3JR_P"'WR3^06U_F!M' MX[_(3MBIWEL_M;"=IY+XS4/4\W0NX^JZ79'7VSNJLO#U[VWA<)L.A^0O57;W M56*RLB5%9E,_E<'N"?(.W^3.:6CIP'S/L6S7'+-WO>R[8(KFV>(71F^H68O( M\H,L+-(;:6&9AA4C62,*/B[F(JV/=+Z'=[3;;_<&DBFCD,*H(3&`BH=#A5\9 M'C0@EG?2[.13"]%2^;G8/:W0O\P7^8)\A.MM[-0;KV7\._@=LK:^9W!L78.[ M\!T1MWN?Y'YOK3??<]*F6VM49MZ;J+;&3S.YI()Z]<7.\TYR:3T,$<<`BY4L MMOW?DKDO9KZTU6TNZ7[NJR2(UPT%L)4APX6LS!(JA=0"KX>ER2Q7O=S/9\R\ MR7L%PL5Q%80!9&17$8DDTZJ$8$='8<`3(QEUHJA7#M[YA?,7`?(ZD^)W4?S> MR._MFY_YC_R]>M(?E10]4?&C<6\-N[>^2O5'RRS_`'%TFB8+K*#I;-;APXZ- MVWN3'UXP/\3Q4&YHHJL3T[0+4-;7RURS/L\G,.Y\GB">/:=QF^E,UTJ.]M-: M+#-W2^.JGQY(V7Q=+F,E=+`D.[ANF[P3VMA8\T>,)=SMH3((["QV`VIAY\DU-)6U:T=)18^G9W$4,,*JB@CV\(N>:=R-M;!! M)MVXZ(TU,%U6LVE%U%G:E0JZBS'%23GH:[L#!MT(FG+%"-3MI!-$:K-0*HKQ M-`%'D`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`8?PO^(_O_P#`?P?[K]F<'[YU M6?TWU.O0_A:===/=K\.GX?BUZ72.[=_V4G^$[Y_TZ?[+Y_!_P"*[*_TC_Z3O]'OVW\=^VE_T<_WQ_O)_P`O MC[/R?P3[S]_Q:OM?3?VJVS^LOB6?[H^M\33)X7A>+737]71I_#7^TTXK\73% M]^Y-%Q^\?I=&I-?B:./X-6KSI\%<^G4_KO\`V5CQ;/\`]$_^@#P_Q_._W!_T M>_Z._'_>G^Z47]YO[H_WD'T7TU-1T:-'Q:>[3I\]'&F=/''2`WI_ MLA?WW7O^D'_93OO_`.*;F_T7_P!Z_P#1)Y?XQ_>&N_OA_W[G^ M(_:>O^*:_-_E%_:VU_KCHO?HOWEX>E/%T>-33I&C73RT4TZOP4IV]);C^KFJ MU^J^BU5;P]7A\=1U::^>JM:?BXYZKO\`YBO4/PEWKMFNR_=7RUZJZ6Z,K_CE MG,.VT*OJ?H_?590=(8_;.[JG>NYOAEN*JV=7[VVUOK-[-K9Z>HEV]'N]%2DH M3C\33UQ26H&O).Y\UVDXCVOENYN]V%ZK:Q-<1@SED"+>J'"/&'`($AAXMKD* MU`#_`##9[%<+$;G>+>WM#`0`8X7/AT-3;%E.EJ5R@D\J+6G5FO7,?Q2BVGU] M%LN?J*IQ<>+Z3CV74UPVNNY*ADV7&O1$\RY>&GW"NZ)=E`M@141ID!2F3[=0 MNL`!7QYC-Q>&[%R)-4^L#7I_M/\`&*4[='B?VE.VM-7ET)K4;,(;86Y@*:8M M-=.KX/T>/=JT?!7NI6G1=OF=L#H#?&Q\;)EN_.ENC=M8/M+<<^[6W[UWTEV7 MT7N_M#(4=%15M#V_@=_8ZGH$[-PM28*O%RQ9W"YA:T'S"M@\E.3OE6]WFTNY M!%LUW=SO;KH\.6>*X2($D&%HR3X3"H<&-TT\-!HW17OUMMEQ;J7W*WMXEF;5 MK2*2%I"`")0XIX@P5[T:O'4*CI]^`&W?B-M+X0X/;?Q\W]2=H_'##Y+OBCW3 MV%OO&4V%Q^[-S+VKV&WR#RV[<3EML;-P&.P\W9#9\30Q8RDPB4*@4BM0>)V8 MYRGYDN>;)I]YLS;[XPMRD<9+%%\*/Z<(0[L6\/P\ES)J^+OJ.E>PQ;9#L<,5 MIO^+F+PM2FZ:< MY/IR'J>IJL=N*;K[<<>7K\+3[(AJ)Y]XT?7[9*313QO7-C5G&DPF0%B5NW73SIUI!RVUK,MFUFL1U9B\.H;0U2-% M>\)JX9TU\J]%_P#Y<^`_EN;5^.VR-N?&'??0W9])A>@-IX_>7851AMB[=[9W MAU13X21,?GNZ\'58C`;OQ6.K\3K:IASE%3(D=Q+&HX]G7/$W/=SOEW/O]G>6 M[/>N4C#2-"DVK*P,&9"0>!C8GT/1=RQ%RM#ML,6TW-O-IMU#N0BRM'3C*"%8 M`CB'`^?1HNR_]D5_CW67^F#_`&53^\7]SZ[_`$/_`.D;_1/_`!+^X7\/I?O_ M`/1[_>3][^Z?\*\6K^'_`.2>"W]CV';#^M_A7_[L_>/@^*/&\+QJ>)4T\33^ M.M?B[J]&UW_5WQ;/Z[Z/Q?#/A:_#KHIG1J_#3TQ3I8;,_P!E6_TS[L_T?_Z! M_P#9@O[OT7]]O[H_W#_TL_W7^UPGV/\`>+^$?[^K^"_9?PS3Y_V?%]I_9\'M M-=?UB_=5M];]9^Y=9\/7XG@ZZM73J[-5=?#-=7SZ40?N;Z^;Z;Z;]YZ1KTZ/ M$TXIJIW4IIXXII^70@9C_1'_`!+?'\?_`-'/\7_N6G^DK^,?W9_B7^COPY7Q M_P!^/O?\J_N7]O\`>V^__P`AT>>W'D]HHOWGX=IX/C^%XOZ6G73Q)7 M3\/=P^72E_HM=QXGA:_#_4KIKHS\=?P<>../SZ"/J/\`V3#^XFU?]!G^RT_Z M-O\`2,W]R?\`1E_HR_N?_I;^WKO^/9_NW_N)_P!(OV7W.G[;_/7"ULM7SYY9LV+KP:O'LZW;MD8-DI#Z+ZC`;48E$;055^#2NWT')@EL4!;) MK(BSU@.;MG':>&\C2YY,&6&:PXDODTS42*4C6:`=-<)Z.%$B1:)?*DI$4F+! MI[!+;&Q#M[+MVQB#;#Z]$G1HQXZK54N;Z&5GTS/-!,$852KA@VFD\H7]-(G? MVO_P`MCV;[K>A'.I_A\=*(NZ4-P=;T5L743MXGK#P]X\*Q8L//3X\__[KI^G MOYO]!9A?&P(6N$^!""8XV4A4956&&6K$)!-BZ_&GX(4?/7>071S]M1!M`!!T M&6*<.>**;[Y%0P\]7\4'W%<8QIB0A@9!!1@`%MY(8%T`R,9CB`:!B!!$))EQ MDDF-O"><6#;2,5<55Q)_H&DU711*-;:V1J2>69,:91 M!(17J=2E(XJL5T8KP-732DE50*B/3=1V5!)N$`O`E<]- M=^Q3A$X[E%$@M`&B5-H!0(`DMC"*9D)>51/-DB]&<^Z[!>V(D5#R7G1E1IMV MEU$1&R7%+T;YUJM0C@I5*K!"!R,DR<+D9K1C(_"2-Z:6K5VV7A`01ZPQO,": M9)IGJD6(E69E;&RRC)HAYB:*H+GB")U??07).E"X/P]$Y4C%OANWFII"EXCB2FT`6Q*G`-@N$,]; M2XLC08LB85"H6A=40@DI_/-MSMBG>A"C4A>$?- M="G+2JQ;K$93APO&(4*.NIOVC"7`@8#H4%!#5OF8ES5KG,L1:SH):HBV$K&X MJ!I-2IM8PH2TUKF.9"4K"`D29I0#-6MZB*)+`@LH$&NQL(4#F<[!CH60R,DH M=$)+0R.&L[2PY"J#_FA1EW!P*@+)[J+8W_4M:YU54-F M39.C@J"W$"5>Q(^1<:)&BK@10+;%D`E!WT$0B3#O:40OBC2?)$:5D6VT01)\ M3`@1-I($3`H28)+P$7,XB"*EA5EM9B1N,J2;8+?.:&OG= M^M+0.M&PS!6=@1/2&@,60F*S0+1,B/,T0J;6H:9H>C(=:#(GO\7(+"SG_GS+ M"GD4R;EU36&U4<2#S,"ZE+3"?J"QIP7KF18XYE,G^RS=H;`H">Y(@@2SN]>I M&E:0(R9!*&[`SI@F!+*7U&-=C=%'/LBB084Z]*$@V:>-IG:X:_5H($XIUA6) ME,/BB"86;DR+V71E%FL,!Q[QN`],>]*J&DDMITYMWM4$XC,^THBG92A$0=/0 MC&A08YSYR,9-_H,V#<8C3$MEZC__$1X$2DT["+$;C[!&H[PAQ!58;0T]&@.E M'VK#@H-+:TQ;U=;K?$<[6*L:4J;ZCT1I]$<*>54.T]"*F-6II6%QEV`S=+CM M&'9;1UD8H2HEUW](JY.+6ZM`]J&;K!2SF&E8_A'9',.8EVZ6(QC-+4;+B%%1 M8O0\VMG&='S"1XQ";[ATVP]&AY1#STA"%BYQ1!HR%Y8[Z08B%$GG;=VBG76V M119%F$CH=-B(2+`,)B"<+,D$M5W;.,6[.;&8EE)GI!)]QCT01%F(`F'J?-1_OG$G',Y M3P#_D8*9MA!QQ(W:_L^(A0+^D:"(SPG/=\+3T1NJCB5ZND7+_D;=]Z0%9.^# MR83*@.&.IB%;SFDJ04YXH\/MJ%J+=8HB$>WC[E0G=PC"C(,1&J8ZLD?1!W%]:XAC5F;0V)OM"%VFF"0HH0%%O$J<&!)!':+(*R$#/DH2OQW<@72 M;1%2I]"0)8@U"#@02@,`X5RCVI9A\THR&2D-\*#N2H=ZD_BUD7`@ON8UDWPC M'+*M5'!_2RID0@Y3'LX6L&*!AU)9OM3,W;,^89DYS07K#S_#!VG^V/E.CBQT M!7WX+9#4R'82>Y$D:*-T1JPHTQ=2`NUFAP3:J*A&4N7*,<+W($Q95"6)WMA] M=,]ALY9-U^M,=DPC*H89V61&]G$HZP%L(*C$B"4T GRAPHIC 7 p67422p67422z0001.gif GRAPHIC begin 644 p67422p67422z0001.gif M1TE&.#EAWP`T`/<``````(````"``("`````@(``@`"`@,#`P,#/CX^KJZO'Q\?CX^/_[\*"@I("`@/\```#_ M`/__````__\`_P#______RP`````WP`T```(_@#_"1Q(L*#!@P@3*ES(L*'# MAQ`C2IQ(L:)%A@G&0WLJ7+ES!C+E2G0,*[ M@O$4M)')LZ?/GP[;Z)274`$\H$B3*FUY0`'+A4/P+9U*M>I#?`HEGU"AZL\%W@ MB&TB$%[,^%]37A,5'&A,.2^\PQ$I3*C,^>V\OA/;*=C8N;15>$(G1ZYKNK72 M>2:E1E[KNC92FNHH:K;-VR>ODQ0?5.A-7"8$S'8W%U_>\IX"HA%_2V+N$)ZZ M=M0;*E@7,5X$Y'KG_K&+(-LCA9/3LRMT,`0Q`\B$YTE0H`X?;8Z&CTM0KY`O MQ`D*I$?8>5P]X!$[DM7$7T*?*1"!:@F1)1EC34$`W4<`_J.`<@L>!($$#\0C M%`7K'!!//`>P(P$$%4CB%V/?0?@12CFYU6%!AOT3P3T"\7+/>!*T\0Y\E"G0 M7DB7'?`;AS<2!-A-ZSC`FW/E?>3?$'F0<`A=%FF_I] M,X&;V#SN#5G22I`9EZ"66^%R6G8('P>DH!!-D0ED\A!)Q0PVD(ZD$'3$#L8O?:5?`_8='SCB1T.D5F/`,% MB.-V&H+[SV^C:JH2KP9/_`^P0V#I:*$-*2I0.]\]4.6&,0H4+T*&G?1N0;]U M>]9EMSH4K$#..5KN/\ZQ1E]!WV$G5$$`ECGR26VDME"_!'UV@"3MM,/.//-( MHG)#OPDI#U^!]2RE0$UQ;)`\*AU-$)D,(#J5_L4*T6F7C0DY!YFM0DD`-CR? ME250L`>8%!A6G@KT0-$'[4;09277.J%=J0ZQ3L]J^_4`X%Y^)T'"!SU@$@0B M?T2//"?&`P\\\9"I()< M1G;B4P?,.&(N@DC"`=\I"#Y4=Q+:T(0E[2"-,I M![C/&&TEISEJ"F;B6LH!V@"!=D`'7XL[FZ9.(H_S$.4S$I"/2>(D$`3]L$O#@11X5X,?%.(5M=7'322#PLZ;X\1[.$9(4__&`-.V)3^U[ ME-`8@R`&C"U=E4(=01"D`$-*)E:(O*4R+X40$!$E:;Q;IC0A(K=I6O.:V,RF /-K?)S6YZ\YO@]&9````[ ` end -----END PRIVACY-ENHANCED MESSAGE-----

EX-99.1

exv99w1

EX-99.2

exv99w2